In Vitro Susceptibilities of Aerobic and Facultative Non-Spore- Forming Gram-Positive Bacilli to HMR 3647 (RU 66647) and 14 Other Antimicrobials
|
|
- Simon Watkins
- 6 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p Vol. 42, No /98/$ Copyright 1998, American Society for Microbiology In Vitro Susceptibilities of Aerobic and Facultative Non-Spore- Forming Gram-Positive Bacilli to HMR 3647 (RU 66647) and 14 Other Antimicrobials FRANCISCO SORIANO,* RICARDO FERNÁNDEZ-ROBLAS, RAQUEL CALVO, AND GLORIA GARCÍA-CALVO Department of Medical Microbiology, Fundación Jiménez Díaz, Madrid, Spain Received 20 October 1997/Returned for modification 31 December 1997/Accepted 19 February 1998 The comparative in vitro activity of the ketolide HMR 3647 (RU 66647) and those of structurally related macrolide-lincosamide-streptogramin compounds (erythromycin, roxithromycin, azithromycin, clarithromycin, josamycin, lincomycin, pristinamycin, and quinupristin-dalfopristin) as well as those of benzylpenicillin, doxycycline, vancomycin, teicoplanin, levofloxacin, and rifapentine against 247 aerobic and facultative nonspore-forming gram-positive bacilli were determined by an agar dilution method. The ketolide was active against most organisms tested except Corynebacterium striatum, coryneform CDC group I2, and Oerskovia spp. The frequency of resistance to erythromycin and other macrolides as well as that to lincomycin was high. Pristinamycin and, to a lesser extent, quinupristin-dalfopristin were very active, but resistance to these agents was present in some strains of Rhodococcus equi, Listeria spp., C. striatum, Erysipelothrix rhusiopathiae, and Oerskovia spp. HMR 3647 was very active against all erythromycin-sensitive and many erythromycin-nonsusceptible strains, especially Corynebacterium minutissimum, Corynebacterium pseudodiphtheriticum, Corynebacterium amycolatum, and Corynebacterium jeikeium. In vitro resistance to benzylpenicillin was common, but doxycycline, vancomycin, and teicoplanin were very active against most organisms tested except E. rhusiopathiae, against which glycopeptide antibiotics were not active. The in vitro activity of levofloxacin was remarkable, but resistance to this agent was common for C. amycolatum, Corynebacterium urealyticum, C. jeikeium, and Oerskovia spp. strains. Rifapentine was also very active in vitro against many organisms, but resistance to this agent was always present in E. rhusiopathiae and was very common in C. striatum and C. urealyticum. Infections caused by Corynebacterium species and other facultative, non-spore-forming, gram-positive bacilli have emerged (3, 6, 13), and most recent studies show an alarming rate of antibiotic resistance among such organisms (6, 9, 12, 13, 15, 18). Resistance to -lactams, clindamycin, erythromycin, azythromycin, ciprofloxacin, and gentamicin is quite frequent, with vancomycin, doxycycline, fusidic acid, and prystinamycin being the agents that are most active in vitro (6, 12, 13, 15, 18). Ketolides are a new class of macrolide-like antibiotics having a mechanism of action like those of macrolides but with greater in vitro activity against multidrug-resistant gram-positive organisms, including staphylococci, enterococci, pneumococci, and anaerobes (4, 5, 7, 14). In the present study we compared the in vitro activity of the ketolide HMR 3647 (RU 66647) with the activities of 14 other agents (including 8 macrolide-lincosamide-streptogramin antibiotics) against more than 240 isolates of aerobic and facultative non-spore-forming gram-positive bacilli. (Part of this work has been presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 28 September to 1 October 1997 [16].) * Corresponding author. Mailing address: Department of Medical Microbiology, Fundación Jiménez Díaz, Avenida de Reyes Católicos 2, Madrid, Spain. Phone: Fax: E- mail: fsoriano@microb.net. MATERIALS AND METHODS Bacterial strains. A total of 210 aerobic and facultative, non-spore-forming, gram-positive bacilli isolated from clinical samples in our laboratory were examined. In addition, 37 other clinical isolates, kindly provided by L. Martínez- Martínez (Department of Microbiology, University of Seville, Seville, Spain), were also included. All strains were collected from 1987 to Prior to testing, strains were subcultured, checked for purity, and reidentified by standard techniques (2), with additional tests (6) performed if necessary. Antimicrobial agents. HMR 3647 (RU 66647), roxithromycin, azithromycin, clarithromycin, levofloxacin, vancomycin, teicoplanin, and rifapentine were obtained from Hoechst-Marion-Roussel (Romainville, France); lincomycin and benzylpenicillin were from Fluka Chemie AG (Buchs, Switzerland), quinupristin-dalfopristin (30/70) and pristinamycin were from Rhône-Poulenc-Rorer (Collegeville, Pa., and Vitry sur Seine, France, respectively); josamycin was from ICN Biomedicals, Inc. (Aurora, Ohio), erythromycin was from Pierrel (Milan, Italy), and doxycycline was from Sigma Chemical Co. (St. Louis, Mo.). MIC determinations. The MICs were determined by a standard agar dilution method (11) in Mueller-Hinton agar supplemented with 5% defibrinated sheep blood. The plates were incubated aerobically at 35 C for 24 or 48 h, as required, to determine the MIC endpoint. Breakpoints for susceptibility were those proposed by the National Committee for Clinical Laboratory Standards, as follows: erythromycin, 0.5 g/ml; clarithromycin, azythromycin, benzylpenicillin, and levofloxacin, 2 g/ml; doxycycline and vancomycin, 4 g/ml; and teicoplanin, 8 g/ml (11). For antibiotics for which the National Committee for Clinical Laboratory Standards has no proposed breakpoint and only for comparison purposes, we used the following breakpoints for susceptibility: HMR 3647 and lincomycin, 0.5 g/ml; josamycin, roxithromycin, rifapentine, and quinupristindalfopristin, 1 g/ml; and pristinamycin, 2 g/ml (1, 7, 17). Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, and Escherichia coli ATCC were used as controls and were tested up to eight times. RESULTS The results of the tests in which the MICs for the clinical isolates were determined are presented in Table 1. HMR 3647 was very active against most organisms tested (MIC at which 1028
2 VOL. 42, 1998 SUSCEPTIBILITY OF GRAM-POSITIVE BACILLI TO KETOLIDES 1029 TABLE 1. MICs of HMR 3647 and 14 other antimicrobial agents for aerobic and facultative non-spore-forming gram-positive bacilli Antimicrobial agent MIC ( g/ml) Range 50% 90% C. urealyticum (27) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Vancomycin Rifapentine Pristinamycin Quinupristin-dalfopristin C. jeikeium (34) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Rifapentine Pristinamycin Quinupristin-dalfopristin C. amycolatum (37) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Rifapentine Pristinamycin Quinupristin-dalfopristin Corynebacterium pseudodiphtheriticum (16) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Vancomycin Rifapentine Pristinamycin Quinupristin-dalfopristin C. striatum (25) HMR Erythromycin Clarithromycin Continued on following page
3 1030 SORIANO ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 1 Continued Antimicrobial agent MIC ( g/ml) Range 50% 90% Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Rifapentine Pristinamycin Quinupristin-dalfopristin C. minutissimum (13) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Rifapentine Pristinamycin Quinupristin-dalfopristin A. haemolyticum or A. pyogenes (18) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Rifapentine Pristinamycin Quinupristin-dalfopristin Listeria spp. (35) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Vancomycin Rifapentine Pristinamycin Quinupristin-dalfopristin E. rhusiopathiae (6) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Continued on the following page
4 VOL. 42, 1998 SUSCEPTIBILITY OF GRAM-POSITIVE BACILLI TO KETOLIDES 1031 TABLE 1 Continued Antimicrobial agent MIC ( g/ml) Range 50% 90% Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Vancomycin Rifapentine Pristinamycin Quinupristin-dalfopristin R. equi (16) HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Vancomycin Rifapentine Pristinamycin Quinupristin-dalfopristin Others (20) a HMR Erythromycin Clarithromycin Roxithromycin Azithromycin Josamycin Lincomycin Benzylpenicillin Doxycycline Levofloxacin Teicoplanin Vancomycin Rifapentine Pristinamycin Quinupristin-dalfopristin a C. afermentans (n 5), Turicella otitidis (n 2), Brevibacterium spp. (n 5), Oerskovia spp. (n 4), and coryneform CDC group I2 (n 4). 50% of isolates are inhibited [MIC 50 ], 0.25 g/ml) except Corynebacterium striatum, coryneform CDC group I2, and Oerskovia spp. The MIC 50 and MIC 90 for Corynebacterium jeikeium were 0.12 and 128 g/ml, respectively. The frequency of resistance to erythromycin and the other macrolides tested as well as to lincomycin was very high, with the activity of clarythromycin being superior to those of the other macrolides tested. The frequency of resistance to benzylpenicillin was high, particularly in Corynebacterium urealyticum, C. jeikeium, Rhodococcus equi, Oerskovia spp., Corynebacterium afermentans, and coryneform CDC group I2. The activities of doxycycline and quinupristin-dalfopristin were also very high, although resistance to the latter was observed mainly in Listeria, R. equi, Erysipelothrix rhusiopathiae, C. striatum, and Oerskovia strains. Levofloxacin was also very active against most strains tested except Corynebacterium amycolatum, C. urealyticum, C. jeikeium, and Oerskovia strains. Rifapentine was active against many species tested, but resistance to this agent was always present in E. rhusiopathiae and was very common in C. striatum, C. urealyticum, and C. amycolatum. Vancomycin, teicoplanin, and pristinamycin were very active against most strains tested, with only E. rhusiopathiae being resistant to glycopeptide antibiotics and some strains of R. equi, Listeria spp. (but no Listeria monocytogenes), and Oerskovia spp. being resistant to pristinamycin. The activity of the ketolide against erythromycin-susceptible and -nonsusceptible strains is represented in Table 2. HMR 3647 was very active against all erythromycinsensitive strains and 32 of the 34 (94%) erythromycin-intermediate (MICs, 1 to 4 g/ml) strains. Among the 80 erythromycin-resistant (MICs, 8 g/ml) strains tested, 44 (55%) were susceptible to HMR 3647 and the MICs for the remaining strains were 1 g/ml. Such resistance occurred mainly in C. striatum, C. urealyticum, and C. jeikeium strains, of which only 5, 17, and 61% of erythromycin-resistant strains, respectively, were inhibited by a concentration of 0.5 g HMR 3647 per ml. DISCUSSION The results of this study confirm those of previous publications showing a high incidence of erythromycin-resistant
5 1032 SORIANO ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 2. Activity of HMR 3647 against erythromycin-susceptible and nonsusceptible aerobic and facultative, non-spore-forming, gram-positive bacilli Erythromycin susceptibility a (no. of isolates) HMR 3647 MIC ( g/ml) 50% 90% C. urealyticum (27) Susceptible (11) Nonsusceptible (16) C. jeikeium (34) Susceptible (9) Nonsusceptible (25) C. amycolatum (37) Susceptible (1) Nonsusceptible (36) C. pseudodiphtheriticum (16) Susceptible (6) Nonsusceptible (10) C. striatum (25) Susceptible (4) Nonsusceptible (21) C. minutissimum (13) Susceptible (7) Nonsusceptible (6) a Susceptibility was considered to be an MIC of 0.5 g/ml. strains among aerobic and facultatively anaerobic, non-sporeforming, gram-positive bacilli (12, 13, 15, 18). Therefore, erythromycin, once considered to be the drug of choice for the treatment of infections caused by these organisms, can no longer be recommended for use in treatment unless an in vitro study confirms the erythromycin susceptibility of the infecting strain. The ketolide was very active against erythromycin-susceptible strains (MIC 90 range, to 0.25 g/ml). On the other hand its activity against erythromycin-nonsusceptible strains varied (MIC 90 and MIC 50 ranges, 0.06 to 128 and 0.03 to 16 g/ml, respectively). Most erythromycin-intermediate strains (94%) were susceptible to the ketolide, as were 55% of the erythromycin-resistant strains. Resistance to HMR 3647 was particularly common among erythromycin-resistant strains of C. striatum and C. urealyticum. Macrolides other than erythromycin showed activity similar to that obtained with erythromycin, with clarithromycin being much more active due not only to its higher susceptibility breakpoint (2 g/ml) but also to its greater intrinsic activity. Lincomycin was active against all Arcanobacterium haemolyticum and Arcanobacterium pyogenes strains as well as many strains of E. rhusiopathiae. Pristinamycin was very active against most strains tested, with only some strains of R. equi, Listeria spp., and Oerskovia spp. being resistant to this drug. The in vitro activity of quinupristin-dalfopristin (both drugs are pristinamycin derivatives) was similar to that of pristinamycin, although the MIC of pristinamycin was two to eight times lower than those obtained with the combination derivatives. The combination quinupristin-dalfopristin has recently been tested against L. monocytogenes and C. jeikeium (1, 10, 14), and the MICs were slightly lower than (1, 10) or similar to (14) those that we obtained for C. jeikeium. However, published data for L. monocytogenes indicate that the MIC 90 s for this strain are between 1 and 2 g/ml (1, 10, 14), while our results gave slightly higher MIC 90 s(4 g/ml). Resistance to macrolide-lincosamide-streptogramin antibiotics was probably due to target modification (erythromycin, josamycin, and lincomycin resistance) in most strains (8). However, resistance from drug inactivation (lincomycin resistance and erythromycin and josamycin sensitivity) probably occurred in C. jeikeium, C. striatum, C. minutissimum, R. equi, and Listeria spp. (8). In addition, resistance to macrolide-lincosamidestreptogramin antibiotics due to other non-well-defined mechanisms may have been present in C. urealyticum, C. minutissimum, R. equi, and Listeria spp. The data obtained with glycopeptide antibiotics (vancomycin and teicoplanin), doxycycline, and pristinamycin confirm those presented in previously published reports describing the marked activities of these compounds (12, 15). On the other hand, our data also indicate that benzylpenicillin remains very active against many organisms but not against C. urealyticum, C. jeikeium, R. equi, and Oerskovia spp. so that it can be used, alone or in combination with aminoglycosides, for the treatment of infections, including endocarditis, caused by penicillinsusceptible organisms. Data on the in vitro activity of levofloxacin against the organisms studied are scarce, and this antibiotic is very active against many species but not against C. amycolatum, C. urealyticum, and C. jeikeium. Although this study does not compare the activity of levofloxacin with those of other quinolones, the results obtained in this study are very similar to those published previously for the activity of ciprofloxacin against other gram-positive bacilli (9, 13, 15). Rifapentine was very active against most organisms tested, although resistance in E. rhusiopathiae and isolates of C. urealyticum and C. striatum was quite common. The results with rifapentine are very similar to those previously published for rifampin against coryneform organisms (13, 15). ACKNOWLEDGMENTS This study was supported by a grant from Hoechst-Marion-Roussel. G.G.C. was a recipient of a scholarship from the Fundación Conchita Rábago, Madrid, Spain. REFERENCES 1. Barry, A. L., P. C. Fuchs, and S. D. Brown Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J. Antimicrob. Chemother. 39(Suppl. A): Clarridge, J. E., and C. A. Spiegel Corynebacterium and miscellaneous irregular gram-positive rods, Erysipelothrix, and Gardnerella, p In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology. American Society for Microbiology, Washington, D.C. 3. Coyle, M. B., and B. A. Lipsky Coryneform bacteria in infectious diseases: clinical and laboratory aspects. Clin. Microbiol. Rev. 3: Ednie, L. M., S. K. Spangler, M. R. Jacobs, and P. Appelbaum Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents. Antimicrob. Agents Chemother. 41: Ednie, L. M., S. K. Spangler, M. R. Jacobs, and P. C. Appelbaum Antianaerobic activity of the ketolide RU compared to activities of four macrolides, five -lactams, clindamycin, and metronidazole. Antimicrob. Agents Chemother. 41: Funke, G., A. von Graevenitz, J. E. Clarridge III, and K. A. Bernard Clinical microbiology of coryneform bacteria. Clin. Microbiol. Rev. 10: Jamjian, C., D. J. Biedenbach, and R. N. Jones In vitro evaluation of a novel ketolide antimicrobial agent, RU Antimicrob. Agents Chemother. 41: Leclercq, R., and P. Courvalin Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob. Agents Chemother. 35: Martínez-Martínez, L., A. I. Suárez, M. C. Ortega, and E. J. Perea Comparative in vitro activities of new quinolones against coryneform bacteria. Antimicrob. Agents Chemother. 38: Moore, L. S., B. Schneider, and W. J. Holloway Minimal inhibitory concentrations of quinupristin/dalfopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes. J. Antimicrob. Chemother. 39(Suppl. A): National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa. 12. Philippon, A., and F. Bimet In vitro susceptibility of Corynebacterium group D2 and Corynebacterium jeikeium to twelve antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 9:
6 VOL. 42, 1998 SUSCEPTIBILITY OF GRAM-POSITIVE BACILLI TO KETOLIDES Riegel, P., R. Ruimy, R. Christen, and H. Monteil Species identities and antimicrobial susceptibilities of corynebacteria isolated from various clinical sources. Eur. J. Clin. Microbiol. Infect. Dis. 15: Schülin, T., C. B. Wennersten, R. C. Moellering, Jr., and G. M. Eliopoulos In vitro activity of RU 64004, a new ketolide antibiotic, against grampositive bacteria. Antimicrob. Agents Chemother. 41: Soriano, F., J. Zapardiel, and E. Nieto Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents. Antimicrob. Agents Chemother. 39: Soriano, F., R. Calvo, and R. Fernández-Roblas In vitro activity of ketolide HMR 3647 (RU 66647) against gram-positive bacilli, abstr. F-118, p In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 17. Statement 1996 CA-SFM Zone sizes and MIC breakpoints for nonfastidious organisms. Clin. Microbiol. Infect. 2(Suppl. 1): Williams, D. Y., S. T. Selepak, and V. J. Gill Identification of clinical isolates of nondiphtherial Corynebacterium species and their antibiotic susceptibility patterns. Diagn. Microbiol. Infect. Dis. 17:23 28.
Validation of Vitek version 7.01 software for testing staphylococci against vancomycin
Diagnostic Microbiology and Infectious Disease 43 (2002) 135 140 www.elsevier.com/locate/diagmicrobio Validation of Vitek version 7.01 software for testing staphylococci against vancomycin P.M. Raney a,
More informationSteven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 2063 2069 Vol. 54, No. 5 0066-4804/10/$12.00 doi:10.1128/aac.01569-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative
More informationDiscrepancies in the recovery of bacteria from multiple sinuses in acute and chronic sinusitis
Journal of Medical Microbiology (2004), 53, 879 885 DOI 10.1099/jmm.0.45655-0 Short Communication Correspondence Itzhak Brook ib6@georgetown.edu Received 1 March 2004 Accepted 18 May 2004 Discrepancies
More informationACCEPTED. Comparison of disk diffusion and agar dilution methods for erythromycin and
AAC Accepts, published online ahead of print on January 00 Antimicrob. Agents Chemother. doi:./aac.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationReceived 21 April 1997/Returned for modification 30 June 1997/Accepted 28 August 1997
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1997, p. 3258 3263 Vol. 35, No. 12 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Comparison of Agar Dilution, Broth Microdilution, E-Test,
More informationReceived 30 May 2004/Returned for modification 31 August 2004/Accepted 25 September 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2005, p. 408 413 Vol. 49, No. 1 0066-4804/05/$08.00 0 doi:10.1128/aac.49.1.408 413.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationShirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate
Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC
More informationExtremely High Incidence of Macrolide and Trimethoprim- Sulfamethoxazole Resistance among Clinical Isolates of Streptococcus pneumoniae in Taiwan
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1999, p. 897 901 Vol. 37, No. 4 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Extremely High Incidence of Macrolide
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationRetapamulin Inhibition of Translation and ACCEPTED. 50S Ribosomal Subunit Formation in. Staphylococcus aureus Cells
AAC Accepts, published online ahead of print on 11 June 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.00475-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationIn vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae
AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment
More informationMAJOR ARTICLE METHODS
MAJOR ARTICLE Urinary Tract Infection due to Corynebacterium urealyticum in Kidney Transplant Recipients: An Underdiagnosed Etiology for Obstructive Uropathy and Graft Dysfunction Results of a Prospective
More informationThe activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs
Journal of Antimicrobial Chemotherapy (984) 4, Suppl. B, 39-43 The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs
More informationAntimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationResistance to new anti-grampositive. Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France
Resistance to new anti-grampositive agents Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France Recently available antimicrobials against MDR Gram-positive infections Cyclic lipopeptide: daptomycin
More informationSUPPLEMENTAL TESTING. Tan Thean Yen
SUPPLEMETAL TESTG Tan Thean Yen To Supplement Definition: add as a supplement to what seems insufficient "supplement your diet" Why supplement? urrent methods don t work well Additional information provided
More informationNon-Beta-lactam Antibiotic: Testing and Desensitization
Non-Beta-lactam Antibiotic: Testing and Desensitization David A. Khan, MD Professor of Medicine Allergy & Immunology Program Director Division of Allergy & Immunology 1 Disclosures n Research Grants n
More informationTesting for Induction of Clindamycin Resistance in Erythromycin-Resistant Isolates of Staphylococcus aureus
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2005, p. 1716 1721 Vol. 43, No. 4 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.4.1716 1721.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More information/01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2001, p. 2604 2608 Vol. 45, No. 9 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.9.2604 2608.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationRelationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2004, p. 2398 2402 Vol. 42, No. 6 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.6.2398 2402.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationTigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
Diagnostic Microbiology and Infectious Disease 52 (2005) 181 186 www.elsevier.com/locate/diagmicrobio Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationSpectrum of vancomycin and susceptibility testing
Spectrum of vancomycin and susceptibility testing Olivier Denis Service de Microbiologie Laboratoire de bactériologie Service de Microbiologie Hôpital Erasme Glycopeptides Vancomycin 1958 < Amycolatopsis
More informationProtein Synthesis Inhibitors
Frank Lowy Protein Synthesis Inhibitors This lecture discusses a diverse group of antibiotics that are grouped together because they all have a common mechanism of action they are protein synthesis inhibitors.
More informationSynergism of Fosfomycin-Ampicillin and Fosfomycin-
ANTIMICROBiAL AGENTS AND CHEMoTHERAPY, May 1978, p. 75-79 66-484/78/13-75$2./ Copyright 1978 American Society for Microbiology Vol. 13, No. 5 Printed in U.S.A. Synergism of Fosfomycin-Ampicillin and Fosfomycin-
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Macrolides - Lincosamides Aminoglycosides Tetracyclines Chloramphenicol Oxazolidinones Streptogramins Lecture Outline Description of protein synthesis - translation Antibiotics
More informationOverview of Translation (2) Protein Synthesis Inhibitors. Overview of Translation (3) Lecture Outline. Overview of Translation (1)
Protein Synthesis Inhibitors Macrolides - Lincosamides Aminoglycosides Tetracyclines Chloramphenicol Streptogramins Oxazolidinones Overview of Translation (2) Initiation trna + AA binds translation elongation
More informationtelithromycin oral streptococci 140 telithromycin TEL azithromycin AZM clarithromycin CAM roxithromycin RXM levofloxacin LVFX ampicillin ABPC
telithromycin 3 0 3 0 oral streptococci 0 telithromycintelazithromycin AZMclarithromycinCAMroxithromycinRXMlevofloxacinLVFXampicillinABPC erythromycinem TEL EM erm mef 5 Streptococcus mitis MIC90 ml TEL
More informationReport: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves
Veterinary and Agrochemical Research Centre Report: antimicrobial resistance in commensal Enterococcus spp. from poultry, pigs, cows and veal calves P. Butaye 1 Introduction Enterococci are regarded as
More informationAbstract. Introduction
ORIGINAL ARTICLE BACTERIOLOGY In-Vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years R. Krausse
More informationACCEPTED ANTIPNEUMOCOCCAL ACTIVITY OF LBM415 COMPARED TO OTHER AGENTS. KLAUDIA KOSOWSKA-SHICK KIM L. CREDITO GLENN A. PANKUCH BONIFACIO DEWASSE
AAC Accepts, published online ahead of print on 20 November 2006 Antimicrob. Agents Chemother. doi:10.1128/aac.01150-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationIdentification of clinically relevant Corynebacterium spp., Arcanobacterium. Running title: Gram-positive bacilli identified by MALDI-TOF MS.
JCM Accepts, published online ahead of print on 15 February 2012 J. Clin. Microbiol. doi:10.1128/jcm.05821-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Identification
More informationRifampin Resistance. Charlottesville, Virginia i0w organisms in Trypticase soy broth (BBL Microbiology
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1980, p. 658-662 0066-4804/80/04-0658/05$02.00/0 Vol. 17, No. 14 Treatment of Experimental Staphylococcal Infections: Effect of Rifampin Alone and in Combination
More informationRESEARCH NOTE. 86 Clinical Microbiology and Infection, Volume 12 Number 1, January 2006
86 Clinical Microbiology and Infection, Volume 12 Number 1, January 2006 REFERENCES 1. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26: 1179 1181. 2. Barenfanger J, Drake
More informationDIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05
Date company submitted: 15 Dec 04 Date received by CDER: 15 Dec 04 Reviewer: Fred Marsik, Ph.D. Date assigned: 15 Dec 04 NAME AND ADDRESS OF APPLICANT Wyeth Pharmaceuticals Inc. P.O. Box 8299 Philadelphia,
More informationStreptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin
2009 21 1) 1, 2) 1, 2) 1) 1) 2) 1) 1) 1) 1) 1) 1, 2) 1) 2) 20 2 29 21 1 14 Streptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin (STFX), DX619 S. pneumoniae S. pneumoniae 60
More informationAgainst Aerobic Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1979, p. 6-6 0066-0/79/1-06/05$0.00/0 Vol., No. 6 In Vitro Activity of LY17935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli DENNIS G. DELGADO,
More informationJAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.
More informationAntibiotic treatment of streptococcal and enterococcal endocarditis: an overview
European Heart Journal (1995) 16 {Supplement B), 75-79 Antibiotic treatment of streptococcal and enterococcal endocarditis: an overview P. FRANCIOLI Division of Hospital Preventative Medicine and Department
More informationClinical Failure of Vancomycin Treatment of Staphylococcus aureus Infection in a Tertiary Care Hospital in Southern Brazil
224 BJID 2003; 7 (June) Clinical Failure of Vancomycin Treatment of Staphylococcus aureus Infection in a Tertiary Care Hospital in Southern Brazil Larissa Lutz, Adão Machado, Nadia Kuplich and Afonso Luís
More informationGlobal challenge of antibiotic-resistant Mycoplasma genitalium. by author. Sabine Pereyre
Global challenge of antibiotic-resistant Mycoplasma genitalium Sabine Pereyre USC EA 3671 Mycoplasmal and chlamydial infections in humans INRA - University of Bordeaux -Bordeaux University Hospital National
More informationPharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple Doses
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2001, p. 170 175 Vol. 45, No. 1 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.1.170 175.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationDissemination of Macrolide-Resistant Streptococcus pneumoniae Isolates Containing Both erm(b) and mef(a) in South Korea
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2003, p. 5787 5791 Vol. 41, No. 12 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.12.5787 5791.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationExperimental Endocarditis Caused by Streptococcus sanguis:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1981, p. 1-14 66-484/81/71-5$2./ Vol. 2, No. 1 Experimental Endocarditis Caused by Streptococcus sanguis: Single and Combined Antibiotic Therapy MARIA V. VICENTE,
More informationIdentification of vat(e) in Enterococcus faecalis Isolates from Retail Poultry and Its Transferability to Enterococcus faecium
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2002, p. 3823 3828 Vol. 46, No. 12 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.12.3823 3828.2002 Identification of vat(e) in Enterococcus faecalis Isolates from
More informationComparison of Two Laboratory Techniques for Detecting Mycoplasmas in Genital Specimens. Osama Mohammed Saed Abdul-Wahab, BSc, MSc, PhD*
Bahrain Medical Bulletin, Vol. 32, No. 4, December 200 Comparison of Two Laboratory Techniques for Detecting Mycoplasmas in Genital Specimens Osama Mohammed Saed Abdul-Wahab, BSc, MSc, PhD* Objective:
More informationdoxycycline by using both tetracycline-susceptible and tetracycline-resistant (This work was presented in part at the 33rd Interscience
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1994, p. 2628-2632 0066-4804/94/$04.00+0 Copyright X) 1994, American Society for Microbiology Vol. 38, No. 11 Susceptibilities of Mycoplasma hominis, Mycoplasma
More informationEFFECT OF ANTIMICROBIAL DRUGS ON THE INTESTINAL MICROFLORA: IMPORTANCE OF PHARMACOKINETIC PROPERTIES OF ANTIBACTERIAL AGENTS TOM BERGAN
Old Herborn University Seminar Monograph 3: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. Editors: Carl Erik Nord, Peter J. Heidt, Volker Rusch, and
More informationAntibiotics acting on Protein Synthesis E. Westhof
Antibiotics acting on Protein Synthesis E. Westhof 1. Considérations générales et introductives 1 Facts about Antibiotics Alexander Fleming (1928) discovered penicillin Ignored until early 1940s with extensive
More informationDifferential impact of macrolide compounds in the selection of macrolide nonsusceptible Streptococcus pneumoniae
Differential impact of macrolide compounds in the selection of macrolide nonsusceptible Streptococcus pneumoniae EDITORIAL JM Blondeau Department of Clinical Microbiology, Royal University Hospital and
More informationWhat is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden
What is new in EUCAST 2016 17 South Africa, May, 2016 Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden What is new in EUCAST 2016/17? New organisms with breakpoints (Addendum 2016)
More informationQ-FEVER Q FEVER. CPMP/4048/01, rev. 3 1/7 EMEA 2002
Q FEVER CPMP/4048/01, rev. 3 1/7 General points on treatment Q fever is a zoonosis caused by Coxiella burnetii, an obligate intracellular gram-negative bacterium with high infectivity but with relatively
More informationORIGINAL ARTICLE. Italy
ORIGINAL ARTICLE Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies M. E. Jones
More informationMacrolides, Clindamycin & Ketolides Polymyxins
Macrolides, Clindamycin & Ketolides Polymyxins Kwan Soo Ko Macrolides - Erythromycin - Azithromycin - Clarithromycin Lincosamides - Lincomycin - Clindamycin Unrelated chemically But, many similar biological
More informationIn vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates
AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro
More informationThe first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland
Journal of Antimicrobial Chemotherapy (2002) 50, 1065 1069 DOI: 10.1093/jac/dkf252 The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland Jolanta Krzysztoá-Russjan
More informationReceived 6 October 1995/Returned for modification 27 November 1995/Accepted 29 January 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1996, p. 874 878 Vol. 40, No. 4 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Activities of the Glycylcyclines N,N-Dimethylglycylamido-Minocycline
More informationVentriculoperitoneal Shunt Infection Caused by ACCEPTED. Division of Infectious Diseases, Akron General Medical Center, Akron OH, 1
JCM Accepts, published online ahead of print on 26 March 2008 J. Clin. Microbiol. doi:10.1128/jcm.02141-07 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationEfficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections
SUPPLEMENT ARTICLE Efficacy of Antimicrobial Therapy for Mycoplasma genitalium Infections Lisa E. Manhart, 1,3 Jørgen Skov Jensen, 4 Catriona S. Bradshaw, 5 Matthew R. Golden, 2,3 and David H. Martin 6
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationProtein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8
Protein Synthesis Inhibitors Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 These drugs selectively inhibit bacterial protein synthesis. The selectivity is due to the differences between bacterial and human
More information(multidrug-resistant Pseudomonas aeruginosa; MDRP)
220 2009 (multidrug-resistant Pseudomonas aeruginosa; MDRP) 21 4 1 21 10 4 amikacin (AMK), imipenem/cilastatin (IPM), ciprofloxacin (CPFX) multidrug-resistant Pseudomonas aeruginosa (MDRP) CHROMagar TM
More informationNon-Spore-Forming Gram-Positive Bacilli: Corynebacterium, Propionibacterium, Listeria, Erysipelothrix, Actinomycetes, & Related Pathogens
4010_1-16 2/11/04 9:27 AM Page 212 Non-Spore-Forming Gram-Positive Bacilli: Corynebacterium, Propionibacterium, Listeria, Erysipelothrix, Actinomycetes, & Related Pathogens 13 The non-spore-forming gram-positive
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00869.x Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy I. Serrano, M. Ramirez, the Portuguese Surveillance
More informationDepartment of Infection, GKT School of Medicine, St Thomas Hospital, London, UK
ORIGINAL ARTICLE Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin A. King, T. Bathgate and I. Phillips Department
More informationA Novel Lantibiotic Acting on Bacterial Cell Wall Synthesis Produced by the Uncommon FLAVIA MARINELLI. DBSM, University of Insubria, Varese Italy
A Novel Lantibiotic Acting on Bacterial Cell Wall Synthesis Produced by the Uncommon Actinomycete Planomonospora sp. FLAVIA MARINELLI DBSM, University of Insubria, Varese Italy Vicuron Pharmaceuticals,
More informationAnti-Microbial Drugs
Name: Date: Monday March 7 th 2011 Class: I "Pharmacology Anti-Microbial Drugs Lecture 5 د. حيدر الشكرجي Macrolides: Anti-Microbial Drugs Erythromycin was the 1 st of macrolides to find clinical application,
More informationTreatment of prosthetic joint infection. Alex Soriano Department of Infectious Diseases Hospital Clínic of Barcelona
Treatment of prosthetic joint infection Alex Soriano Department of Infectious Diseases Hospital Clínic of Barcelona Barret L, et al. The clinical presentation of prosthetic joint infection. J Antimicrob
More informationMicrobiological and host features associated with corynebacteriosis in cancer patients: a five-year study
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 104(6): 905-913, September 2009 905 Microbiological and host features associated with corynebacteriosis in cancer patients: a five-year study CAS Martins 1,
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2001, p. 183 190 Vol. 39, No. 1 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.1.183 190.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Contemporary
More informationORIGINAL ARTICLE. Pneumococcal acute otitis media in children
ORIGINAL ARTICLE Pneumococcal acute otitis media in children G. Kouppari 1, A. Zaphiropoulou 1, G. Stamos 1, V. Deliyianni 1, N. Apostolopoulos 2 and N. J. Legakis 3 1 Microbiology Laboratory, 2 ENT Department
More informationOverview of Tigecycline and Its Role in the Era of Antibiotic Resistance
BJID 2006; 10 (June) 203 Overview of Tigecycline and Its Role in the Era of Antibiotic Resistance Flávia Rossi, Denise Andreazzi University of São Paulo, LIM 03; São Paulo, SP, Brazil The increasing antimicrobial
More informationAn evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus
Asian Biomedicine Vol. 4 No. 1 February 2010; 141-145 Brief communication (Original) An evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus
More informationTHE STRONGEST RESISTANCE OF Staphylococcus aureus TO ERYTHROMYCIN IS CAUSED BY DECREASING UPTAKE OF THE ANTIBIOTIC INTO THE CELLS
CELLULAR & MOLECULAR BIOLOGY LETTERS http://www.cmbl.org.pl Received: 06 February 2012 Volume 17 (2012) pp 633-645 Final form accepted: 07 September 2012 DOI: 10.2478/s11658-012-0034-3 Published online:
More informationBiofilms: Álvaro Pascual MD, PhD Department of Microbiology
Biofilms: Role on Pathogenesis and Treatment of UTIs. Álvaro Pascual MD, PhD Department of Microbiology University of Seville. Spain. Medical devices-related infections 1. 35 millions/year in USA 2. Most
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationMacrolides & Ketolides. Objectives. Protein Synthesis
Macrolides & Ketolides Elizabeth D. Hermsen, Pharm.D. Infectious Diseases Research Fellow University of Minnesota College of Pharmacy bjectives Participant should be able to explain macrolide/ketolide
More informationlife-threatening infections
Vancomycin Vancomycin has become increasingly important in the treatment of life-threatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal
More informationSynercid I.V. (quinupristin and dalfopristin for injection)
Synercid I.V. (quinupristin and dalfopristin for injection) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Synercid and other antibacterial drugs, Synercid should
More informationMupirocin Rationale for the EUCAST clinical breakpoints, version th July 2010
Mupirocin Rationale for the EUCAST clinical breakpoints, version 1.0 6 th July 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationVancomycin Rationale for the EUCAST clinical breakpoints, version June 2010
Vancomycin Rationale for the EUCAST clinical breakpoints, version 2.1 17 June 2010 Introduction The glycopeptides are a class of agents composed of amino acid residues and attached sugars. Glycopeptides
More informationHaemophilus influenzae from four laboratories in one Canadian City
Journal of Antimicrobial Chemotherapy (988), -9 Haemophilus influenzae from four laboratories in one Canadian City Julie Righter" and Ingrid Luchstnger* 'Department of Microbiology, University of Toronto;
More informationNew guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. D. C. Shanson
Journal of Antimicrobial Chemotherapy (1998) 42, 292 296 New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis JAC D. C. Shanson Microbiology Department,
More informationAerobic bacteria isolated from diabetic septic wounds
Aerobic bacteria isolated from diabetic septic wounds Eithar Mohammed Mahgoub*, Mohammed Elfatih A. Omer Faculty of Pharmacy, Omdurman Islamic University Department of Pharmaceutical Microbiology, Omdurman
More informationComparision of Antibiotic Susceptibility Testing As Per CLSI and Eucast Guidelines for Gram Negative Bacilli
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 7 Ver. X (July. 2016), PP 01-05 www.iosrjournals.org Comparision of Antibiotic Susceptibility
More informationAntibiotic resistance pattern of streptococcus pyogenes isolated from clinical samples with special reference to quinolone resistance
Original Research Article DOI: 10.18231/2394-5478.2017.0022 Antibiotic resistance pattern of streptococcus pyogenes isolated from clinical samples with special reference to quinolone resistance Thipperudraswamy.
More informationReceived 16 September 1999/Returned for modification 24 December 1999/Accepted 31 January 2000
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2000, p. 1575 1580 Vol. 38, No. 4 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. A Novel Multiresistant Streptococcus
More informationUse of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone
Zurenko et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:46 RESEARCH Open Access Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationLabquality External Quality Assessment Programmes General Bacteriology 1 3/2014
Labquality External Quality Assessment Programmes General Bacteriology 1 3/2014 Photos and text: Markku Koskela, M.D., Ph.D. Clinical microbiology specialist Nordlab Oulu, Finland Specimen 31/2014 Abscess
More informationEvernimicin (SCH27899) Inhibits both Translation and 50S Ribosomal Subunit Formation in Staphylococcus aureus Cells
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2000, p. 1413 1417 Vol. 44, No. 6 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Evernimicin (SCH27899) Inhibits
More informationActivities of Ertapenem, a New Long-Acting Carbapenem, against Penicillin-Sensitive or -Resistant Pneumococci in Experimental Meningitis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2003, p. 1943 1947 Vol. 47, No. 6 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.6.1943 1947.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationSusceptibility of Cephalothin-Resistant Gram-Negative Bacilli
ANTIMICROBIAL AGENTS AND CHEmOTHERAPY, Mar. 1978, p. 484489 0066-4804/8/0013-0484$02.00/0 Copyright 1978 American Society for Microbiology Vol. 13, No. 3 Printed in U.S.A. Susceptibility of Cephalothin-Resistant
More informationResistance among Streptococcus pneumoniae Clinical Isolates by Use of the E Test
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1994, p. 159-163 0095-1137/94/$04.00+0 Copyright 1994, American Society for Microbiology Vol. 32, No. 1 Detection of Penicillin and Extended-Spectrum Cephalosporin
More informationCharacterization of Antimicrobial Resistance in Streptococcus pyogenes Isolates from the San Francisco Bay Area of Northern California
JOURNAL OF CLINICAL MICROBIOLOGY, June 1999, p. 1727 1731 Vol. 37, No. 6 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Characterization of Antimicrobial
More informationSurveillance of Enterococci in Belgium. M. Ieven, K. Loens, B. Jans and H. Goossens
Surveillance of Enterococci in Belgium M. Ieven, K. Loens, B. Jans and H. Goossens Surveillance of Enterococci in Belgium Overview Introduction and epidemiological surveillance Results of isolates received
More informationMacrolide-resistant phenotypes of invasive Streptococcus pneumoniae isolates in Serbia
Arch. Biol. Sci., Belgrade, 64 (4), 1377-1382, 2012 DOI:10.2298/ABS1204377G Macrolide-resistant phenotypes of invasive Streptococcus pneumoniae isolates in Serbia Ina GajiĆ, NataŠa Opavski, Vera MIJAČ
More information